EU medicine approvals

Eye health Medicines Approved in the EU (EMA)

Medicines the European Medicines Agency has recommended for use in the European Union on this topic.

Each number has its full source under its own list below.

Medicines authorised in the EU

4 medicines (authorised now). Newest first. Each links to its EMA page.

At the source

  • Tepezza

    Active substance: teprotumumab

    EMEA/H/C/006396

  • Vevizye

    Active substance: ciclosporin

    EMEA/H/C/006250

  • Ikervis

    Active substance: ciclosporin

    EMEA/H/C/002066

  • Ozurdex

    Active substance: dexamethasone

    EMEA/H/C/001140

Source: European Medicines Agency, Centrally authorised human medicines (EPAR), authorised now. Retrieved 12 Nov 2026.

Benchmarks on eye health

Countries side by side on public measures for this topic.

All benchmarks

Market reports on eye health

Search all
Digital Health

AI in Ophthalmology

Worldwide · 2024–2034

View report Public Health

Cataract and Avoidable Blindness Public Health Report

Worldwide · 2024–2034

View report Medical Devices

Cataract Surgery Devices

Worldwide · 2024–2034

View report Public Health

Childhood Vision and Refractive Error Public Health Report

Worldwide · 2024–2034

View report Pharmaceuticals

Diabetic Retinopathy Drugs

Worldwide · 2024–2034

View report Public Health

Diabetic Retinopathy Public Health Report

Worldwide · 2024–2034

View report

From our blog

All stories

Eye Health Supplements: Screens, Ageing and Vision

2.2 billion people have a vision impairment. One supplement formula has strong trial evidence, but only for a…

Read

EU medicine approvals on related topics

All topics

Acuitas market sizes and forecasts are only in our full reports. How we use public data.